Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men

Inclusion Criteria: * Subjects are Chinese MSM and/or TGW and must be 18 years or older at the time of screening. * Subjects of male sex at birth and who have sex with men, who in the 6 months prior to screening report one or more of the following risk criteria: * Unprotected (condomless) receptive anal intercourse with one or more partners. * More than five partners in the 6 months prior to enrolment (regardless of condom use and HIV serostatus, as reported by the enrolee). * Reported STI with syphilis, gonorrhea, chlamydia, chancroid, or lymphogranuloma venereum. Subjects in a monogamous relationship with an HIV-1 seronegative partner or a virologically-suppressed HIV-1 + partner for \>1 year are not eligible for participation. * Males, agree to appropriate use of contraceptive measures during heterosexual intercourse. * Subjects who have non reactive fourth generation HIV test and undetectable HIV-1 RNA at screening. * Capable of giving signed informed consent. Exclusion Criteria: * Subjects with known moderate to severe hepatic impairment as per liver function test criteria outlined below. * Subject who, in the investigator's judgment, poses a significant suicide risk. * The Subject has a tattoo or other dermatological condition overlying the gluteus region. * Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease. * Use of PrEP or post exposure prophylaxis (PEP) within the last 30 days prior to screening. * Current use or anticipated need for use high dose aspirin or other anticoagulants including antiplatelet medications that would interfere with the ability to receive intramuscular (IM) injections. * Exposure to an experimental drug and/or experimental vaccine within 28 days or 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the screening. * Anti-tuberculosis therapy. * Alcohol use that in the judgment of the investigator would interfere with the subject's ability to complete study procedures. * Active injection drug use that in the judgment of the investigator would interfere with the subject's ability to complete study procedures. * Any medical condition, including psychiatric conditions, that in the judgment of the investigator would interfere with the subject's ability to complete study procedures. * A reactive HIV test at screening. * A positive Hepatitis B surface antigen. * A positive Hepatitis C antibody with an HCV viral ribose nucleic acid (RNA) above the lower limit of detection. * Any of the following laboratory values at screening: * Hemoglobin (Hgb) \<11 gram per deciliter (g/dL). * Absolute neutrophil count \<750 cells per cubic millimeter (cells/mm\^3). * Platelet count \<100,000 cells/mm\^3. * Presence of a coagulopathy defined by an international normalized ratio (INR)\>1.5 or a partial thromboplastin time (PTT)\>45 seconds. * Creatinine clearance \<60 milliliter per minute (mL/min) using the Cockroft-Gault equation. * Aspartate aminotransferase (AST) \>1.5 times upper limit of normal (ULN). * Direct Bilirubin \>2.0 milligram per deciliter (mg/dL). * Co-enrolment in any other HIV interventional studies.